We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

ASTHMA THERAPEUTICS MARKET ANALYSIS

Asthma Therapeutics Market, by Drug Class (Corticosteroids, Beta2-Agonists (Long-acting and Short-acting), Leukotriene Inhibitors, Long-acting Muscarinic Antagonists (LAMA), Interleukin Antagonists, Anti-immunoglobulin E (IgE) Agents, Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids, and Others), and Others), by Route of Administration (Oral, Inhalation, and Injection), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published In : Jun 2019
  • Code : CMI2698
  • Pages :157
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Global Asthma Therapeutics Market Insights

Asthma is a type of chronic respiratory disease, which is characterized by attacks of breathlessness and wheezing. Asthma can occur at any stage, though it is the most common disease in children. Asthma attacks are linked to respiratory infections and environmental factors such as allergens, tobacco, smoke, and indoor and outdoor pollution. Indoor pollution factors include mold, chemicals, strong odors, and house dust whereas outdoor pollution factors include air pollution, allergens, tobacco, and smoking. Such factors are responsible for development and exacerbation of asthma.

The global asthma therapeutics market was valued at US$ 17,582.2 million in 2018, and is expected to witness a CAGR of 1.9% during the forecast period (2018 – 2026). The market is also expected to Surpass US$ 20.4 Billion by 2026.

Figure 1. Global Asthma Therapeutics Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)

ASTHMA THERAPEUTICS MARKET

To learn more about this report, Request sample copy

Source: Coherent Market Insights Analysis (2019)

Rise in number of respiratory disease cases is expected to drive growth of the global asthma therapeutics market.

Increasing prevalence of respiratory diseases is expected to drive global asthma therapeutics market growth. For instance, according to the World Health Organization’s (WHO) report 2016, around 235 million people suffer from asthma worldwide, annually. Asthma is a progressive and chronic life-threatening respiratory disease. Hence, increasing number of respiratory disease cases support the global asthma therapeutics market growth.

Moreover, increasing awareness activities are contributing to the global asthma therapeutics market growth. For instance, in May 2019, Koninklijke Philips N.V., launched campaign to increase awareness of asthma and related respiratory diseases, especially in children. This campaign was titled as ‘Help Your Child Fight against Asthma’.

Furthermore, product recall is the major restraining factor which is expected to hamper the growth of asthma therapeutics market. For instance, in August 2018, Camber Pharmaceuticals received product recall letter from U.S. Food and Drug Administration (USFDA) for its Montelukast Sodium Tablets. These tablets are recalled because. Montelukast Tablet bottles labeled as Montelukast Sodium Tablet but it contains Losartan Potassium Tablets.

Global Asthma Therapeutics Market- Regional Analysis

North America asthma therapeutics market is expected to account for the largest market share during the forecast period, owing to increasing number of product approvals by regulatory authorities in this region. For instance, in September 2018, U.S. Food and Drug Administration (FDA) announced approval of new Xolair (containing-Omalizumab) prefilled syringe formulation, for treatment of allergic asthma. Xolair is manufactured by Novartis AG.

Moreover, increasing regulatory approvals of new drug for treatment of asthma is expected to boost forecast value of asthma therapeutics market in this region. For instance, in October 2018, U.S. Food and Drug Administration (USFDA) announced approval of new drug Dupixent (contains- Dupilumab), developed by the Regeneron Pharmaceuticals, for the treatment and prevention of pulmonary/respiratory diseases including moderate-to-severe asthma.

Furthermore, Asia Pacific is expected to hold significant market share in the asthma global therapeutics market over the forecast period, owing to increasing product launches by key players in this region. For instance, in April 2019, Cipla announced launch of its new inhaler Niveoli in India. It is India’s first extra-fine particle Beclomethasone-formoterol combination Hydrofluoroalkane (HFA) inhaler for adults. It is indicated for the treatment of obstructive airways diseases (OAD) such as asthma and Chronic Obstructive Pulmonary Disease (COPD).hence increasing number of product launches will support the growth of asthma therapeutics market.

Figure 2: Global Asthma Therapeutics Market Value (US$ Mn), By Region

ASTHMA THERAPEUTICS MARKET

To learn more about this report, Request sample copy

Source: Coherent Market Insights Analysis (2019)

Global Asthma Therapeutics Market - Competitive Landscape

Key players operating in the asthma therapeutics market include GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.

Share

Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.